Drug-drug interaction pharmacokinetic study with the Raf kinase inhibitor (RKI) BAY 43-9006 administered in combination with irinotecan (CPT-11) in patients with solid tumors.

作者信息

Mross K, Steinbild S, Baas F, Reil M, Buss P, Mersmann S, Voliotis D, Schwartz B, Brendel E

机构信息

Tumor Biology Center, Albert-Ludwigs-University Freiburg, Germany.

出版信息

Int J Clin Pharmacol Ther. 2003 Dec;41(12):618-9. doi: 10.5414/cpp41618.

DOI:10.5414/cpp41618

PMID:14692719

Abstract

摘要

相似文献

Drug-drug interaction pharmacokinetic study with the Raf kinase inhibitor (RKI) BAY 43-9006 administered in combination with irinotecan (CPT-11) in patients with solid tumors.

Int J Clin Pharmacol Ther. 2003 Dec;41(12):618-9. doi: 10.5414/cpp41618.

Results of phase I pharmacokinetic and pharmacodynamic studies of the Raf kinase inhibitor BAY 43-9006 in patients with solid tumors.

Int J Clin Pharmacol Ther. 2002 Dec;40(12):580-1. doi: 10.5414/cpp40580.

A phase I clinical and pharmacokinetic study of the Raf kinase inhibitor (RKI) BAY 43-9006 administered in combination with doxorubicin in patients with solid tumors.

Int J Clin Pharmacol Ther. 2003 Dec;41(12):620-1. doi: 10.5414/cpp41620.

Correlation of ERK-phosphorylation and toxicities in patients treated with the Raf kinase inhibitor BAY 43-9006.

Int J Clin Pharmacol Ther. 2004 Nov;42(11):648-9. doi: 10.5414/cpp42648.

Antitumor effect and potentiation or reduction in cytotoxic drug activity in human colon carcinoma cells by the Raf kinase inhibitor (RKI) BAY 43-9006.

Int J Clin Pharmacol Ther. 2003 Dec;41(12):616-7. doi: 10.5414/cpp41616.

Results from an in vitro and a clinical/pharmacological phase I study with the combination irinotecan and sorafenib.

Eur J Cancer. 2007 Jan;43(1):55-63. doi: 10.1016/j.ejca.2006.08.032. Epub 2006 Nov 13.

BAY 43-9006: preclinical data.

Curr Pharm Des. 2002;8(25):2255-7. doi: 10.2174/1381612023393026.

ERK1/2 phosphorylation: a biomarker analysis within a phase I study with the new Raf kinase inhibitor BAY43-9006.

Int J Clin Pharmacol Ther. 2002 Dec;40(12):567-8. doi: 10.5414/cpp40567.

Activity of the Raf kinase inhibitor BAY 43-9006 in patients with advanced solid tumors.

Clin Colorectal Cancer. 2003 May;3(1):16-8. doi: 10.1016/s1533-0028(11)70463-7.

Phase I study to determine the safety and pharmacokinetics of the novel Raf kinase and VEGFR inhibitor BAY 43-9006, administered for 28 days on/7 days off in patients with advanced, refractory solid tumors.

Ann Oncol. 2005 Oct;16(10):1688-94. doi: 10.1093/annonc/mdi310. Epub 2005 Jul 8.

引用本文的文献

Phase 1 study of sorafenib and irinotecan in pediatric patients with relapsed or refractory solid tumors.

Pediatr Blood Cancer. 2021 Nov;68(11):e29282. doi: 10.1002/pbc.29282. Epub 2021 Aug 12.

Pharmacodynamic and Pharmacokinetic Markers For Anti-angiogenic Cancer Therapy: Implications for Dosing and Selection of Patients.

Eur J Drug Metab Pharmacokinet. 2018 Apr;43(2):137-153. doi: 10.1007/s13318-017-0442-x.

PharmGKB summary: sorafenib pathways.

Pharmacogenet Genomics. 2017 Jun;27(6):240-246. doi: 10.1097/FPC.0000000000000279.

Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on pyrimidines, pyridines and pyrroles.

Clin Pharmacokinet. 2011 Sep;50(9):551-603. doi: 10.2165/11593320-000000000-00000.

Targeted therapies to treat non-AIDS-defining cancers in patients with HIV on HAART therapy: treatment considerations and research outlook.

Curr Opin Oncol. 2009 Sep;21(5):445-54. doi: 10.1097/CCO.0b013e32832f3e04.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验